Shanghai Securities News, China Securities Network (Reporter Zhang Xue) – CanSino announced on December 20 that its Diphtheria, Tetanus, acellular Pertussis (component), Haemophilus influenzae type b (conjugate), and ACYW135 Meningococcal Polysaccharide (conjugate) Combined Vaccine (hereinafter referred to as the "DTcP-Hib-MCV4 Combined Vaccine") has officially initiated a Phase I clinical trial and has enrolled the first participant. The trial aims to evaluate the safety and immunogenicity of the vaccine in individuals aged 2 months to 6 years.

With the increasing variety of vaccines available in China, the use of multiple-dose vaccines has raised challenges such as increased discomfort for children during vaccination, higher costs for healthcare authorities, difficulties and expenses in vaccine management, reduced compliance among young children, and a heightened possibility of suspected adverse reactions. Consequently, the development of combined vaccines that simultaneously prevent multiple diseases has become a key trend in new vaccine R&D.

The company stated that initiating the development of the DTcP-Hib-MCV4 combined vaccine aligns with both its product pipeline strategy and the market demand for multivalent vaccines, aiming to build a differentiated competitive advantage. The vaccine received the "Drug Clinical Trial Approval Notice" in February 2025.

Reference：https://finance.eastmoney.com/a/202512203597453267.html